Last reviewed · How we verify
NCT00490204
Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis
Phase 3 trial testing Cetirizine in Rhinitis, Allergic, Perennial in 239 participants. Completed in 3 October 2007.
3 October 2007
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Primary purpose | treatment |
| Enrollment | 239 |
| Start date | 27 July 2007 |
| Primary completion | 3 October 2007 |
| Estimated completion | 3 October 2007 |
| Sites | 28 locations across Japan |
Drugs / interventions tested
- Cetirizine (cetirizine) — full drug profile →
Conditions studied
- Rhinitis, Allergic, Perennial — all drugs for Rhinitis, Allergic, Perennial →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
Adults 2 to 14, any sex, with Rhinitis, Allergic, Perennial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study objective is to verify the superiority of CTZ DS to the placebo groups in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00490204
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cetirizine
Trials testing the same drug.
- NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project · Phase 3 · not yet recruiting
- NCT05946551 — Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial · Phase 3 · terminated
- NCT06126991 — Organ Protective Effect of Cetirizine In Patients With Severe Burns · Phase 1, PHASE2 · unknown
- NCT06019728 — A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme · Phase 4 · completed
- NCT06039137 — The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment · completed
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00490204 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 29 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00490204.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing